November 6, 2020
A day before the FDA’s aducanumab advisory committee meeting, Eisai CEO Haruo Naito at the company’s earnings conference on November 5 expressed his expectations for what could potentially be the first Alzheimer’s drug in 17 years. Partner Biogen’s anti-amyloid antibody...read more